Literature DB >> 34851464

Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity.

Amir Sternfeld1,2, Safa Rahmani3,4, Jennifer L Rossen3,4, David L Zhang3, Yuping D Li3,5,6, Victor L Quan3,5,7, Russell Huang4, Hawke H Yoon8,9.   

Abstract

PURPOSE: To report long-term fluorescein angiography (FA) findings in consecutive patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB), whose ROP seemed to have resolved clinically.
METHODS: Data were retrospectively collected for all patients with IVB-treated type 1 ROP who underwent an exam under anesthesia (EUA) and FA at 60 weeks post-gestational age (PGA) or older at a tertiary medical center between 2011 and 2020. FA results were reviewed for pathological vascular findings.
RESULTS: Twenty-nine eyes of 16 patients were included. Mean gestational age and birth weight were 25.3 ± 1.5 weeks and 762.2 ± 189.8 g, respectively. The mean age at the time of EUA and FA was 23.4 ± 15.8 months. All eyes had a peripheral avascular zone and irregular peripheral branching. Vascular loops were seen in 27 eyes (93.1%) and vascular bulbs and anastomoses in 16 eyes each (55.2%). Additional abnormal findings included leakage (10 eyes, 34.5%), vessels crossing the fovea (5 eyes, 17.2%), tortuous arteries and veins (9 eyes, 31%, and 5 eyes, 17.2%, respectively), and neovascularization (2 eyes, 6.9%). When comparing patients who were less than or greater than 70 weeks PGA at follow-up, FA findings in the group with shorter follow-up were significant for more anastomoses and vascular bulbs (p = 0.002 and p = 0.024, respectively) and trended towards more leakage (45.5% vs. 27.8%, p = 0.331).
CONCLUSION: The vast majority of IVB-treated type 1 ROP eyes suffered from vascular pathologies long after treatment. There may be long-term progression in the vascularization process of the retina in some cases.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bevacizumab; Fluorescein angiography; Retinopathy of prematurity; Vasculature

Mesh:

Substances:

Year:  2021        PMID: 34851464     DOI: 10.1007/s00417-021-05499-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  19 in total

1.  Reactivation of retinopathy of prematurity after bevacizumab injection.

Authors:  Jennifer Hu; Michael P Blair; Michael J Shapiro; Steven J Lichtenstein; John M Galasso; Rashmi Kapur
Journal:  Arch Ophthalmol       Date:  2012-08

2.  Late-onset tractional fibrovascular proliferation post-intravitreal bevacizumab following treatment of retinopathy of prematurity.

Authors:  Swati Agarwal-Sinha; Jade Gieseke Guevara; Sarina M Amin
Journal:  Can J Ophthalmol       Date:  2017-12-16       Impact factor: 1.882

Review 3.  Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.

Authors:  Deborah K VanderVeen; Michele Melia; Michael B Yang; Amy K Hutchinson; Lorri B Wilson; Scott R Lambert
Journal:  Ophthalmology       Date:  2017-03-22       Impact factor: 12.079

4.  A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.

Authors:  Tiffany A Chen; Ryan A Shields; Zachary H Bodnar; Natalia F Callaway; Ira H Schachar; Darius M Moshfeghi
Journal:  Am J Ophthalmol       Date:  2018-10-09       Impact factor: 5.258

5.  Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.

Authors:  B Mueller; D J Salchow; E Waffenschmidt; A M Joussen; G Schmalisch; Ch Czernik; Ch Bührer; K U Schunk; H J Girschick; S Winterhalter
Journal:  Br J Ophthalmol       Date:  2016-06-14       Impact factor: 4.638

Review 6.  Pathophysiology and mechanisms of severe retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Ophthalmology       Date:  2014-10-14       Impact factor: 12.079

Review 7.  Retinopathy of prematurity.

Authors:  Jing Chen; Lois E H Smith
Journal:  Angiogenesis       Date:  2007-02-27       Impact factor: 9.596

8.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

9.  Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.

Authors:  Megan M Geloneck; Alice Z Chuang; W Lloyd Clark; Michael G Hunt; Alan A Norman; Eric A Packwood; Khaled A Tawansy; Helen A Mintz-Hittner
Journal:  JAMA Ophthalmol       Date:  2014-11       Impact factor: 7.389

10.  COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.

Authors:  Guoming Zhang; Mingmin Yang; Jian Zeng; Georgios Vakros; Kangjin Su; Miaohong Chen; Huilin Li; Ruyin Tian; Na Li; Song Tang; Honghui He; Wenjing Tan; Xiangmei Song; Runsen Zhuang
Journal:  Retina       Date:  2017-04       Impact factor: 4.256

View more
  1 in total

Review 1.  Deep learning for ultra-widefield imaging: a scoping review.

Authors:  Nishaant Bhambra; Fares Antaki; Farida El Malt; AnQi Xu; Renaud Duval
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-07-20       Impact factor: 3.535

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.